Financial News · Live Terminal

Page 1025 of 1189

Uni-President Enterprises Unit Buys Structured Deposit Worth 100 Million Yuan

Uni-President Enterprises (TPE:1216) unit China investment acquired a structured deposit product from CTBC Bank's Shanghai branch worth 100 million yuan, according to a Friday Taiwan Exchange filing.Shares gained about 1% in Monday's late morning trade.The product, named Hui Gao Xin Fu 20260028, is a principal-guaranteed, RMB-linked structured deposit.The investment is aimed at generating stable returns through low-risk financial products, the filing said.

TPE:1216

Asia108d ago

Keppel Unit Starts Arbitration vs Vietnam JV Partners Over Land Use Fees

Keppel's (SGX:BN4) subsidiary, Corredance, started an arbitration against its three partners in a Vietnamese joint venture over land fees, according to a Monday filing with the Singapore Exchange.Corredance is seeking declarations that Denver Power, Tien Phuoc Real Estate Joint Stock Company, and Tran Thai Lands, not the company, are fully liable for about 6.877 trillion dong of additional land use fees that the authorities have imposed on their joint venture by the end of 2025.The joint venture was established for constructing, developing and operating residential and mixed-use developments in Ho Chi Minh. It is 40% owned by Corredance.

SGX:BN4

Asia108d ago

China Resources Microelectronics' Q1 Profit Soars 297%, Revenue Jumps 21%

China Resources Microelectronics' (SHA:688396) net profit attributable to shareholders in the first quarter surged 297% to 330 million yuan from 83.2 million yuan a year earlier, according to a Shanghai bourse filing on Saturday.The Chinese semiconductor manufacturer's shares rose 1% during Monday's midday trade.Earnings per share soared 295% year on year to 0.25 yuan from 0.06 yuan.Operating revenue jumped 21% to 2.86 billion yuan from 2.35 billion yuan in the previous year.

SHA:688396

Asia108d ago

Geovis Swings to Loss in Q1

Geovis Technology (SHA:688568) swung to a net loss attributable to shareholders of 148.8 million yuan, or 0.18 yuan per share, in the first quarter, according to a Shanghai bourse filing on Saturday.The Chinese big data system developer's shares dropped 8% during Monday's midday trade.The attributable profit a year earlier was 20.8 million yuan, or 0.03 yuan per share.Operating revenue dropped 59% year on year to 202.7 million yuan from 504.3 million yuan.

SHA:688568

Asia108d ago

Island Pharmaceuticals Works Alongside USAMRIID to Advance Clinical Development For Galidesivir

Island Pharmaceuticals' (ASX:ILA) work alongside the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and Texas Biomedical Research Institute is well progressed, with the next phase of clinical development for its Galidesivir drug candidate expected to start shortly, according to a Monday Australian bourse filing.It received around a AU$143,000 refund under the Australian Government's research and development tax incentive for the fiscal year 2025. The refund relates to eligible expenditure associated with the ongoing development of ISLA-101.It worked alongside Todd Strategy Group and MC2 to advance industry engagement initiatives in the US during the March quarter.Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity against over 20 RNA viruses, including Ebola, Marburg, MERS, Zika, and Yellow fever, the filing added.Its shares were up 1% in recent trading on Monday.

ASX:ILA

Asia108d ago

TeleChoice International Buys Back More Shares

TeleChoice International (SGX:T41) bought back 350,000 shares in the open market on Friday for SG$91,436, according to a Monday filing with the Singapore Exchange.The provider and enabler of innovative info-communications products and services has been mandated to buy back around 45.4 million shares under its existing mandate.

SGX:T41

Asia108d ago

Addvalue Technologies Proposes Spin-off, Nasdaq Listing of Inter-Satellite Data Relay Business; Shares Soar 28%

Addvalue Technologies (SGX:A31) filed an application to the SGX-ST for a proposed spin-off for the listing of its Inter-Satellite Data Relay System business on the Nasdaq Stock Market, according to a Monday filing with the Singapore Exchange.Addvalue Solutions undertakes the business, which involves all communication and commercial activities, involving the IDRS technologies 1 and consisting of the supply of IDRS terminals and/or the provision of services.The SGX informed the company that the spin-off does not amount to a chain listing and is subject to listing requirements and guidelines.Shares of the satellite-based communication surged nearly 28% in Monday trading.

SGX:A31

Asia108d ago

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

ASX:ONE

Asia108d ago

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

ASX:PAR

Asia108d ago

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

SHA:600703

Asia108d ago

Optowide Technologies 2025 Profit Up 2%

Optowide Technologies (SHA:688195) posted 2025 attributable net profit of 70.6 million yuan, up 1.8% from 69.4 million yuan the previous year.Earnings per share went up to 0.55 yuan from 0.54 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue rose 32% year over year to 585.5 million yuan from 445.1 million yuan.Shares of the precision optics and fiber components manufacturer declined 1% in recent trade.

SHA:688195

Asia108d ago

Elixir Energy Holds Largest Net Acreage in Queensland's Taroom Trough After 24% Increase in Discovered Resources, Euroz Hartleys Says

Elixir Energy (ASX:EXR) now holds an estimated contingent resource position of 3.5 trillion cubic feet equivalent (Tcfe) of gas in the Taroom Trough acreage following a 24% increase in discovered resources, giving it the largest net acreage position in the Queensland oil and gas basin, Euroz Hartleys said in an April 24 note.That compares with a basin position of 1.7 Tcfe for peer Omega Oil & Gas (ASX:OMA), the equity research firm said.Elixir Energy's Lorelle-3H well is arguably "the best drilled in the basin to date," with a horizontal length of 1,157 meters and average porosity of over 11%, which materially de-risks the company's upcoming hydraulic fracturing and flow test from the middle of June, Euroz Hartleys said.The company also has a 50% stake in the Diona well, a side project on the fringes of the Taroom Trough that recently returned "encouraging" drilling results to prove potential opportunity for near-term cashflow, the equity research firm said.Euroz Hartleys reiterated its speculative buy recommendation on Elixir Energy with an under-review price target of AU$0.28.Elixir Energy and Omega Oil & Gas' shares each fell past 3% in recent Monday trade.

ASX:EXRASX:OMA

Asia108d ago

China Resources Microelectronics' 2025 Profit Falls 13%, Revenue Rises 9%

China Resources Microelectronics' (SHA:688396) net profit attributable to shareholders in 2025 fell 13% to 660.5 million yuan from 762.5 million yuan a year earlier, according to a Shanghai bourse filing on Saturday.The Chinese semiconductor manufacturer's shares rose 1% during Monday's midday trade.Earnings per share dropped 14% year on year to 0.50 yuan from 0.58 yuan.Operating revenue rose 9.2% to 11.1 billion yuan from 10.1 billion yuan in the previous year.

SHA:688396

Asia108d ago

SEM Holdings Completes HK$44 Million Bond Sale

SEM Holdings (HKG:9929) said it completed the sale of HK$44 million in convertible bonds to Yao Capital , according to a Hong Kong bourse filing Friday.Shares of the electrical and mechanical engineering services firm fell over 7% in late morning trade Monday.The bonds have an initial conversion price of HK$0.11 per share.

HKG:9929

Asia108d ago

Keyence, Fanuc Shares Climb, Chugai Declines as Japan Stocks Mixed After Earnings

Japanese stocks that reported recent earnings traded mixed on Monday, with gains led by companies posting solid profit growth and shareholder returns, while one major drugmaker declined despite higher quarterly earnings.Keyence (TYO:6861) shares jumped 16% after reporting full-year results, with net income attributable to owners of parent rising 12% to 445.19 billion yen as revenue increased 10% to 1.169 trillion yen. The company raised its annual dividend to 550 yen per share from 350 yen.Fanuc (TYO:6954) shares also gained 16% after posting annual results, with net income attributable to owners of parent climbing 13% to 166.54 billion yen, while revenue rose 8% to 857.83 billion yen.The company expects full-year net income attributable to owners of the parent of 184.9 billion yen and revenue of 909.6 billion yen for the financial year ending March 31, 2027. It also raised its annual dividend to 107.09 yen per share from 94.39 yen.Meanwhile, Chugai Pharmaceutical (TYO:4519) fell 16% despite reporting stronger first-quarter earnings. Net income attributable to shareholders rose 19% to 115.42 billion yen as revenue increased 12% to 321.75 billion yen. The company expects full-year revenue of 1.345 trillion yen and core net income of 485 billion yen, with an annual dividend forecast of 132 yen per share.

Nikkei 225TYO:4519TYO:6861TYO:6954

Asia108d ago

Market Chatter: European Lithium Said to Receive Over AU$1 Billion Bid From Nasdaq-Listed Firm

European Lithium (ASX:EUR) is said to be in talks with Critical Metals for a AU$0.58-per-share bid for European Lithium, resulting in a deal value of around AU$1.16 billion, the Australian Financial Review (AFR) reported on Monday, citing unnamed people familiar with the discussions.European Lithium owns 37.5% of the Nasdaq-listed Critical Metals. The Tanbreez rare earths mine in Greenland and the Wolfsberg lithium project in Austria are said to be the driving force behind the merger.Critical Metals received regulatory approval to own 92.5% of the Tanbreez mine on April 20, while European Lithium received approval to own a 7.5% stake.An ASX announcement is expected to be made as early as Tuesday, per the report.European Lithium did not immediately respond to an emailed request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

ASX:EUR

Asia108d ago

Impro Precision Industries Q1 Revenue Climbs 23%

Impro Precision Industries' (HKG:1286) revenue rose 23% to HK$1.43 billion in the first quarter from HK$1.17 billion a year earlier, according to a Monday Hong Kong bourse filing.The company revised its full-year sales forecast to 15% to 20% year-on-year growth, citing order backlog and expected demand recovery in certain end markets.

HKG:1286

Asia108d ago

CapitaLand Ascott Trust Reports Stable Distribution Income in Q1

CapitaLand Ascott Trust (SGX:HMN) reported "relatively stable" distribution income in the first quarter, supported by divestment gains that offset lower gross profit stemming from the closures of The Cavendish London and Madison Hamburg due to renovations.Revenue per available unit rose 1% year over year in the January-to-March period, according to a Monday filing with the Singapore Exchange.As of March 31, total assets stood at SG$8.9 billion, comprising 19,000 units across 106 properties in 16 countries.

SGX:HMN

Asia108d ago

Easou Technology Invests $7.7 Million in Wealth Product Using Idle Top-up Placing Funds

Easou Technology (HKG:2550) said it has subscribed to a $7.7 million wealth management product issued by Huatai International Financial Products, using idle proceeds from its earlier placings, according to a Friday Hong Kong bourse filing.Shares of the digital service firm were down over 1% in Monday's late-morning trade.The investment, guaranteed by Huatai International Financial, carries an annualized return of 1.07% to 5.83% over a term ending March 30, 2027.Easou said the move aims to enhance the utilization efficiency and returns on idle funds while maintaining liquidity.

HKG:2550

Asia108d ago

SSY Group Gets Chinese Regulatory Nod for Production, Registration of Two Products

SSY Group (HKG:2005) said it received Chinese regulatory approval to begin drug production and registration of its diltiazem hydrochloride in injection form, according to a Hong Kong bourse filing Monday.The drug is mainly used to treat a heart condition known as supraventricular tachycardia and the emergency treatment of abnormally high blood pressure during surgery.The firm's propranolol hydrochloride injection was also approved for production and registration by China's National Medical Products Administration.The product is mainly used to treat supraventricular tachyarrhythmias and ventricular arrhythmias.

HKG:2005

Showing 20481-20500 of 23764